Simply Wall St
4 min read
In This Article:
As global markets navigate a complex landscape of inflationary pressures and geopolitical developments, Asian stock markets have shown resilience, with indices in Japan and China posting gains despite external challenges. In this environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that align with favorable economic indicators and market dynamics.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
SpiderPlus (TSE:4192) |
¥502.00 |
¥994.80 |
49.5% |
|
Shin Maint HoldingsLtd (TSE:6086) |
¥1180.00 |
¥2323.25 |
49.2% |
|
Shenzhen Envicool Technology (SZSE:002837) |
CN¥31.63 |
CN¥62.34 |
49.3% |
|
Lucky Harvest (SZSE:002965) |
CN¥35.24 |
CN¥69.28 |
49.1% |
|
Livero (TSE:9245) |
¥1747.00 |
¥3431.97 |
49.1% |
|
Hugel (KOSDAQ:A145020) |
₩351500.00 |
₩699950.46 |
49.8% |
|
HL Holdings (KOSE:A060980) |
₩41300.00 |
₩81367.57 |
49.2% |
|
HDC Hyundai Development (KOSE:A294870) |
₩23300.00 |
₩45966.93 |
49.3% |
|
Dive (TSE:151A) |
¥955.00 |
¥1867.69 |
48.9% |
|
cottaLTD (TSE:3359) |
¥435.00 |
¥856.73 |
49.2% |
Let’s explore several standout options from the results in the screener.
Overview: J&T Global Express Limited is an investment holding company providing integrated express delivery services across multiple countries including China, Indonesia, and Brazil, with a market cap of HK$86.12 billion.
Operations: The company’s revenue segments include Transportation – Air Freight, which generated $10.26 billion.
Estimated Discount To Fair Value: 31.9%
J&T Global Express appears undervalued based on cash flows, trading at HK$9.68, below its estimated fair value of HK$14.22. Despite a low forecasted return on equity of 18.1% in three years, the company shows robust growth potential with earnings expected to grow significantly at 32.7% annually and revenue outpacing the Hong Kong market at 11.1%. Recent results highlight operational strength with a substantial increase in parcel volume year-on-year.
Overview: Giant Biogene Holding Co., Ltd. is an investment holding company that designs, develops, manufactures, and sells skin treatment products featuring recombinant collagen in China, with a market cap of HK$61.82 billion.
Operations: The company’s revenue primarily comes from the research, development, manufacture, and sale of bioactive material-based beauty and health products, totaling CN¥5.54 billion.
